Arcus Biosciences

Yahoo Finance • 2 months ago

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif., October 09, 2024--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, to... Full story

Yahoo Finance • 4 months ago

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

Facility adds operational flexibility and provides funding for the recently announced Phase 3 PEAK-1 study for casdatifan. $150 million committed, of which $50 million was drawn at closing and the remaining $100 million available at Arcus'... Full story

Yahoo Finance • last year

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

– Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 – ALAMEDA, Calif. & HAYWARD, Calif., December 04, 2023--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Arcus Biosciences (NYSE: RCUS) today announce... Full story

Yahoo Finance • last year

Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript

Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Thank you and welcome to the call. Following prepared remarks from the Company, we will open the call for questions. [Operator instructions] T... Full story

Yahoo Finance • 2 years ago

Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update

Four registrational Phase 3 trials evaluating domvanalimab-based combinations are ongoing or expected to start by year-end; Arcus and Gilead Sciences continue to expand their late-stage clinical program for domvanalimab with the goal of es... Full story

Yahoo Finance • 3 years ago

Biotech Stocks Hammered On Roche's Unexpected Failure In Lung Cancer

A Roche failure in lung cancer sent a ripple through biotech stocks on Wednesday, toppling Arcus, BeiGene, Iteos and others.... Full story